Plain-English translation of NCT06785519 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called CD19/BCMA CAR-T cell therapy for people with lupus nephritis — a serious kidney disease caused by lupus — that hasn't improved with standard medications. The treatment uses specially engineered immune cells designed to target and reduce the cells that cause lupus inflammation. Researchers want to confirm this treatment is safe and effective for patients whose lupus kidney disease has come back or stopped responding to other drugs.
Lupus nephritis can be life-threatening and many patients don't improve enough with current treatments or their disease comes back. This medication offers a completely different approach by retraining immune cells, and early studies suggest it may help patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
In this early-stage trial, you would receive an infusion of the specially engineered CD19/BCMA CAR-T cells. The study will carefully monitor your safety and how well the treatment works for your lupus kidney disease. Because this is a very early trial enrolling only 9 patients, you would be closely watched and have frequent medical visits to track how you respond and to catch any side effects quickly.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
He Huang
Collaborators
Yake Biotechnology Ltd.
Enrollment target
~9 participants
Started
January 2025
Primary completion
October 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
He Huang, MD
Zhejiang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.